Inaugural Chiba-UCSD Mucosal Immunology and Immunization Symposium to Be Held Here February 21-22

Chiba University and UC San Diego, collaborators in the new Program in Mucosal Immunology, Allergy and Vaccine Development based at UC San Diego, are hosting the inaugural Symposium in Mucosal Immunology and Immunization on February 21-22, 2017, at UC San Diego.

The abstract submission deadline is February 17.

Register for the Symposium Here

Dr. Peter Ernst

Dr. Peter Ernst

Co-Directors of the program are Peter Ernst, DVM, PhD, Professor of Pathology and Medicine at UC San Diego School of Medicine, and Hiroshi Kiyono, DDS, PhD, Professor, University of Tokyo and Chiba University.

Dr. Ernst is Director of the Center for Veterinary Sciences and Comparative Medicine.

The Chiba University – UC San Diego collaboration is co-sponsored by the International Immunological Memory and Vaccine Forum (IIMVF) and complements the recently-created UC San Diego-La Jolla Institute Immunology Program.

The international initiative was first announced by UC San Diego in May 2016.

Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity

Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The findings, published in Cell on December 1, could have a clinical role in improving efficiency of immunotherapy drugs. … Read the Full Story from the UC San Diego Newsroom

Dennis Carson, MDThe study coauthors include Dennis A. Carson, MD, member of the UC San Diego Resident Faculty in the UC San Diego Stem Cell Program.

Dr. Carson is Emeritus Professor of Medicine in the Division of Rheumatology, Allergy, and Immunology and former Director of the Moores Cancer Center.

Antibody Breaks Leukemia’s Hold, Providing New Therapeutic Approach

In mouse models and patient cells, anti-CD98 antibody disrupts interactions between leukemia cells and surrounding blood vessels, inhibiting cancer’s growth —

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML. … Read the Full Story from the UC San Diego Newsroom

Dr. Mark Ginsberg

Dr. Mark Ginsberg

Department of Medicine Professor Mark H. Ginsberg, MD, co-directed the study with Tannishtha Reya, PhD, professor of pharmacology.

Dr. Ginsberg is Professor of Medicine in the Division of Rheumatology, Allergy & Immunology at UC San Diego School of Medicine and Moores Cancer Center.

Read the study report

Visit Dr. Ginsberg’s Lab Website

Poison Drummer Rikki Rockett Cancer-Free Following Immunotherapy at UC San Diego Health

Rikki Rockett, drummer for the band Poison, got the best news of his life last week: his cancer is gone. Rockett was diagnosed with oral cancer more than a year ago. Several months ago, he came to Moores Cancer Center at UC San Diego Health, where he underwent experimental cancer immunotherapy, which has now eradicated the tumor.

Rockett says he joined the clinical trial not only out of concern about himself, but also about being around for his three-year-old daughter, Lucy, and his seven-year-old son, Jude. … Read the Full Story by Heather Buschman from the UC San Diego Newsroom

Building a Defense Against Zika

UC San Diego researchers leading efforts to find turning point to virus —

On April 18, 1947, a monkey in Uganda’s Zika Forest fell ill with a fever of 103 degrees Fahrenheit, 4 degrees higher than normal. “Rhesus No. 766” was part of a yellow fever virus study. Scientists took a blood sample. They conducted tests. The rhesus monkey had been stricken by something unknown. In time, the revealed virus would be named after the place where it was first discovered.

But for decades to follow, the Zika virus would garner only sporadic and limited scientific attention. It was determined that the virus could infect humans, but symptoms—if there were any—appeared to be mild (fever, joint pain, rash) and passing. Zika wasn’t deemed a significant human health threat until a major outbreak occurred in the Yap Islands north of Australia in 2007, followed by another in French Polynesia in 2013. For the first time, the Zika virus was associated with serious symptoms, including life-threatening neurological disorders. … Read the Full Story from the UC San Diego Newsroom

New International Initiative Will Focus on Immunology Research and Treatments

Chiba University and UC San Diego launch $2 million collaborative partnership —

Immunology – and the idea that many diseases can best be addressed by boosting the body’s own immune response – is one of the hottest areas in medical research and clinical treatment. University of California San Diego School of Medicine and Chiba University School of Medicine in Japan have announced a new collaborative research center to investigate the most promising aspects of immunology, especially the area of mucosal immunology, and to speed development of clinical applications. … Read the Full Story from the UC San Diego Newsroom

Dr. Peter Ernst

Dr. Peter Ernst

Dr. Peter Ernst is co-directing the Chiba University-UC San Diego Immunology Initiative and associated research center.

Peter Ernst, DVM, PhD, is Professor of Medicine (Division of Gastroenterology), Professor of Pathology and Director of the Center for Veterinary Sciences and Comparative Medicine.